ORUKA THERAPEUTICS INC (ORKA) Stock Price, Quote, News and Overview
NASDAQ:ORKA - Nasdaq - US6876041087 - Common Stock - Currency: USD
ORKA Quote, Performance and Key Statistics
ORUKA THERAPEUTICS INC
NASDAQ:ORKA (2/4/2025, 4:30:02 PM)
After market: 14.21 0 (0%)14.21
+0.51 (+3.72%)
The current stock price of ORKA is 14.21 USD. In the past month the price decreased by -31.72%.
ORKA Latest News, Press Releases and Analysis
Discover the top movers in Tuesday's pre-market session.
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis...
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
ORKA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About ORKA
Company Profile
Oruka Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The firm is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. The company is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).
Company Info
ORUKA THERAPEUTICS INC
10170 Church Ranch Way, Suite 100
Westminster COLORADO US
Employees: 4
Company Website: https://orukatx.com/
Investor Relations: http://arcabio.com/investors/
Phone: 17209402200
ORKA FAQ
What is the stock price of ORKA?
The current stock price of ORKA is 14.21 USD.
What is the symbol for ORUKA THERAPEUTICS INC stock?
The exchange symbol of ORUKA THERAPEUTICS INC is ORKA and it is listed on the Nasdaq exchange.
On which exchange is ORKA stock listed?
ORKA stock is listed on the Nasdaq exchange.
Is ORKA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ORKA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ORKA.
Does ORKA stock pay dividends?
ORKA has a dividend yield of 11.77%. The yearly dividend amount is currently 0.
What is the Price/Earnings (PE) ratio of ORKA?
ORKA does not have a PE ratio as the earnings reported over the last twelve months were negative (-54.36).
What is the Short Interest ratio of ORKA stock?
The outstanding short interest for ORKA is 5.78% of its float.
ORKA Technical Analysis
ORKA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORKA. ORKA has a great financial health rating, but its profitability evaluates not so good.
ORKA Financial Highlights
Over the last trailing twelve months ORKA reported a non-GAAP Earnings per Share(EPS) of -54.36. The EPS decreased by 55.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.27% | ||
| ROE | -22.1% | ||
| Debt/Equity | 0 |
ORKA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to ORKA. The Buy consensus is the average rating of analysts ratings from 13 analysts.